跳至主要内容
临床试验/NCT03820102
NCT03820102Unknown不适用

Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With Hepatitis C Viral Infection Treated by Direct Acting Antiviral Drugs

Assiut University0 个研究点目标入组 100 人开始时间: 2019年3月最近更新:
适应症

试验速览

阶段
不适用
入组人数
100
主要终点
SVR12

研究概览

简要总结

  1. Study Changes in lipid profile and the impact of Insulin resistance on virological response in patients with Hepatitis C viral infection treated by Direct Acting Antiviral agents
  2. The assessment of serum vitamin D levels in HCV infected patients and predictive value of pre-treatment serum vitamin D level for achieving sustained virological response at 12 weeks post-treatment

详细描述

Patients and methods:

This cross-sectional study will include 100patients of chronic HCV infection who attend El Raghy Assiut university Hospital, either inpatients or outpatients. Chronic HCV infection will be diagnosed based on detectable HCV RNA with anti-HCV Ab in patient with clinical and/or ultrasonographic criteria of chronic liver disease.

Patients will receive treatment to HCV by DAAs and follow up for 12 weeks to confirm sustained virological response

Method:

Patients presenting in this study will be subjected to the following:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Chronic HCV will receive DAAs for treatment

排除标准

  • Decompensated liver cirrhosis, hepatocellular carcinoma, history of liver transplant
  • Co-existing liver disease (hepatitis B virus, autoimmune hepatitis, human immunodeficiency virus)
  • Extra-hepatic malignancy except after two years of disease free interval.
  • Patients with diabetes mellitus.
  • Patients with Chronic kidney disease.
  • Pregnancy or in ability to use effective contraception.
  • Patients with history of using lipid lowering therapy
  • relapser or failure of previous HCV treatment

结局指标

主要结局

SVR12

时间窗: 12 week after treatment

sustained virological response 12 week after treatment

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mohamed Hassan Abdelgawad

Gastroenterologest and hepatologest, doctor in Assiut Police Hospital

Assiut University

相似试验